Here's Why bluebird bio Inc. Is Surging Again Today
Shares of bluebird bio Inc. (NASDAQ: BLUE), a clinical-stage biotech developing cell-based therapies, are on the move for the second day in a row. Yesterday, the stock jumped in response to a presentation unveiled at the annual meeting of the American Hematological Society, but the pop mostly fizzled by the end of the day.
After taking a moment to digest the data, a handful of Wall Street banks have upgraded their price targets for the stock, driving it 8.4% higher as of 2:45 p.m. EDT on Thursday.
Even though analysts at Wedbush and BTIG both upped their price targets for bluebird bio, investors should be encouraged by the fact that they can't agree on what the company's main value driver will be over the next several quarters.
Source: Fool.com
Bluebird Bio Inc. Aktie
Bluebird Bio Inc. ist kein großer Community-Favorit mit mehr Sell- als Buy-Einschätzungen.
Obwohl das Kursziel für Bluebird Bio Inc. bei 6 € liegt, was über dem aktuellen Kurs von 1.03 € ist, zeigt sich ein Potenzial von 481.68%.
